Lv4
620 积分 2024-10-12 加入
Fabrication and characterization of isotopically enriched 172Yb2O3 targets for break-up fusion studies
1个月前
已关闭
Industry Perspective on the Selection of Regulatory Starting Materials for Synthetic Peptides
3个月前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
3个月前
已完结
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates
3个月前
已完结
Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices
3个月前
已完结
Clearance of solvents and small molecule impurities in antibody drug conjugates via ultrafiltration and diafiltration operation
3个月前
已完结
Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates
3个月前
已完结
Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices
3个月前
已完结
Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers
11个月前
已关闭
Ylide von Heterocyclen, II: Iodonium‐ und Pyridinium‐Ylide von Malonylheterocyclen
1年前
已完结
皖公网安备34019202002308
